A functional single nucleotide polymorphism, 1858C4T, in the PTPN22 gene, encoding a tyrosine phosphatase, has been reported to be associated with type I diabetes and some other autoimmune diseases. To further investigate whether this polymorphism may be a general susceptibility factor for autoimmunity, we performed an association study in five different autoimmune diseases, three previously not tested. We found an association with juvenile idiopathic arthritis (OR ¼ 1.41; P ¼ 0.04), not previously reported, and a tendency for an association with coeliac disease (OR ¼ 1.35; P ¼ 0.08). In primary sclerosing cholangitis, no association was observed (OR ¼ 0.95; P ¼ 0.8). Furthermore, we confirmed the increased risk in rheumatoid arthritis (OR ¼ 1.58; P ¼ 0.001), but could not find support for an association with systemic lupus erythematosus (OR ¼ 0.94; P ¼ 0.8). Altogether, we have provided further evidence of an association between autoimmune diseases and the 1858C4T polymorphism in PTPN22.
Introduction
Autoimmune diseases are characterized by loss of selftolerance causing immune-mediated tissue destruction. Approximately 3-5% of the population is affected by autoimmune diseases, and examples of common autoimmune diseases are type I diabetes (T1D) and rheumatoid arthritis (RA). Autoimmune diseases are multifactorial and caused by an interaction of numerous genetic and environmental factors. There is increasing evidence that autoimmune diseases share some common risk factors. Evidence for shared susceptibility genes is obtained from the observation that several autoimmune diseases tend to cluster in the same families, 1 and also that the chromosomal regions showing linkage to autoimmune diseases tend to overlap. 2, 3 Consequently, when a potential risk factor for an autoimmune disease is discovered, it is of interest to investigate whether the novel risk factor is also involved in other autoimmune diseases.
An interesting gene with regard to autoimmune diseases, which has received much attention lately, is PTPN22, which encodes a lymphoid tyrosine phosphatase (LYP) involved in inhibition of T-cell activation. 4, 5 LYP is an important molecule in the regulation of T-cell antigen receptor signalling in memory/effector T cells. 6 The PTPN22 gene is situated on chromosome 1p13 in a region suggested to be linked with RA 7 and systemic lupus erythematosus (SLE). 8 Protein tyrosine kinases and phosphatases work together to regulate normal immune cell function, 6 and disruption of the sequence involved in this interaction can be of importance in diseases concerning the immune system.
Recently, a single nucleotide polymorphism (SNP; 1858C4T) within the PTPN22 gene was reported to be associated with T1D, 9-11 RA, 12 SLE, 13 Graves' disease 11, 14 and possibly Addison's disease. 14 The disease-associated SNP is situated within the SH3-binding domain of PTPN22, and results in an amino-acid substitution of a conserved arginine with tryptophan in codon 620. The domain is important for binding of the C-terminal Src tyrosine kinase (Csk), and Bottini et al 9 demonstrated that the disease-associated T-allele at 1858C4T disrupts binding of the negative regulatory kinase Csk to LYP. 9 The aim of our study was to address the possible involvement of the PTPN22 polymorphism 1858C4T in a panel of autoimmune diseases, namely RA (N ¼ 520), juvenile idiopathic arthritis (JIA; N ¼ 327), coeliac disease (CD; N ¼ 321), primary sclerosing cholangitis (PSC; N ¼ 219) and SLE (N ¼ 166). No association studies of PTPN22 have previously been reported for JIA, PSC and CD. Patients and controls (N ¼ 562) were from the Norwegian population, except for the CD patients who were both from Sweden and Norway. Statistical power was calculated (http://calculators.stat.ucla.edu/powercalc/) based on the reported association in T1D 9 available at the time our study was initiated. Hence, the following parameters were employed for the power calculations: a carrier frequency of the T-allele of 0.223 (obtained from the Northern American controls in Bottini et al. 9 ) giving an OR ¼ 1.83 with a lower confidence interval of 1.28 and a significance level of 0.05 for a twosided test. In our data sets, we had a power ranging from 87 to 99% given an OR ¼ 1.83 (99% in RA, 97% in JIA, 97% in CD, 93% in PSC, 87% in SLE), or ranging from 22 to 42% given the lower confidence level of OR ¼ 1.28, to observe an effect equal to that reported in T1D. 9 
Results and discussion
The associations observed between carriers of the T-allele at the PTPN22 1858C4T SNP and the five autoimmune diseases studied are presented in Table 1 . Interestingly, we found an association with JIA (OR ¼ 1.41; P ¼ 0.04), which has not been reported previously. In addition, we observed a strongly significant association with RA (OR ¼ 1.58; P ¼ 0.001), thereby confirming the findings of Begovich et al. 12 Unfortunately, data on which RA patients were rheumatoid factor positive (RF þ ) were not available, thus making it impossible to evaluate if the association concurs with patients being RF þ, as suggested by Begovich et al.
12
To obtain a more homogenous group of JIA patients, we excluded the patients with spondyloarthropathy, and interestingly the observed association was more pronounced (N ¼ 199, OR ¼ 1.7, CI [1.16-2.47], P ¼ 0.005). Within this group, only 12 patients were RF þ, and after removing the RF þ patients, the association was kept (N ¼ 113, OR ¼ 1.69, CI [1.15-2.48], P ¼ 0.007). Thus, the association does not seem to correlate with JIA patients being RF þ, as was suggested for RA. 12 The group of patients with spondyloarthropathy, on the other hand, showed no association (OR ¼ 0.99, CI [0.58-1.66], P ¼ 1.0).
CD showed a tendency of association, which did not reach statistical significance (OR ¼ 1.35; P ¼ 0.08). Although the association with CD was not significant at the 5% level, the possibility of PTPN22 being a risk factor could not be discarded, and further studies are needed to clarify the role of PTPN22 in this disease.
We did not observe an association with PSC (OR ¼ 0.95; P ¼ 0.8), nor could we confirm the association found by Kyogoku et al. 13 in SLE (OR ¼ 0.94; P ¼ 0.8). In these two diseases, there were no indications of association in our material (see Table 1 ). SLE was the smallest material in our data set, hence providing the least power to detect an association. The study of Kyogoku et al. 13 included a significantly higher number of SLE patients, and in their total cohort of 525 SLE patients and 520 19 and SLE patients were classified according to ACR. 20 All patients and controls were of Norwegian origin, except half of the CD patients who originated from Sweden. No heterogeneity was observed between the Norwegian and Swedish CD patients. The control group were recruited from the Norwegian Bone Marrow Registry. Genotyping for the 1858C4T SNP (rs2476601) was carried out using allelic discrimination and a TaqMan-by-design assay (Applied Biosystems, Part number 4332072, Foster City, USA) with primer sequences 5 0 -CCAGCTTCCTCAACCACAATAAATG and 5 0 -CAACTGCTCCAAGGATAGATGATGA, and probe sequence TCAGGTGTCC[A/G]TA-CAGG. Genotyping was carried out on whole genome amplified DNA (GenomiPhi DNA amplification kit, Amersham Biosciences), except for the RA and CD materials which were genotyped on genomic DNA. Therefore, eight PSC and 16 control samples were genotyped on both genomic and amplified genomic DNA, which revealed 100% correlation in genotyping. In addition, 11% of the JIA samples were genotyped twice to check the reproducibility of the assay, which was 100%. As an internal control, eight control samples (two C/C, two C/T and four T/T) were present on all plates genotyped. Furthermore, to reduce possible genotyping bias, patient and control samples were run together on the plates. All populations were in Hardy-Weinberg equilibrium. controls, they observed that carrying the T-allele increased the risk of SLE with an OR ¼ 1.48. Hence, retrospectively given this odds ratio, the power in our material was only 42% for correctly rejecting the null hypothesis of no association. Interestingly, the previously reported SLE association was particularly strong in patients being homozygous for the T-allele, conferring an OR ¼ 4.37. 13 In our material, however, no signs of a dose effect were evident (1.2% in patients vs 1.8% in controls).
In studies, like the present, where one is searching for genetic factors having a small effect on the risk, the sample size is instrumental. Our negative findings in PSC and SLE could be due to lack of power to detect a true association in these diseases, and these two diseases comprised the smallest data sets in our study. Thus genotyping in larger materials is warranted before drawing any definite conclusions. Furthermore, the risk allele might not have the same effect in all diseases and all populations, hence making it harder to discover in some cases. It is also possible that another aetiological variant exists in PTPN22, either adding to 1858C4T, or explaining it through linkage disequilibrium. Alternatively, the PTPN22 gene might not harbour a risk allele shared by all autoimmune diseases. In fact, recent results from Begovich et al. 15 showed that the 1858C4T SNP is not associated with multiple sclerosis. Taking our results together with other reports, [9] [10] [11] [12] [13] [14] however, the PTPN22 gene clearly contributes to the development of several autoimmune diseases.
Our studies indicated an association of the 1858C4T polymorphism in the PTPN22 gene with JIA, and possibly with CD, which has not been previously reported, as well as provided further evidence for the involvement of PTPN22 in RA. Interestingly, in our JIA material, the association did not seem to follow the patients being RF þ, as previously indicated for RA. 12 The reported association with SLE 13 could not be confirmed in our material, nor did we find an association with PSC, but these materials are rather small. Hence, although we could not conclusively determine if PTPN22 is involved in autoimmunity in general, we have provided additional evidence for PTPN22 as an autoimmune susceptibility gene.
